Biosyent reports Q3 EPS C$0.20

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Nov 20 2024

0mins

Q3 Revenue Growth: BioSyent reported a Q3 revenue of C$9.56M, an 8% increase compared to Q3 2023, with significant contributions from Canadian pharmaceutical sales growing by 12%.
Year-to-Date Performance: The company experienced a 13% growth in total sales, EBITDA, and NIAT year-to-date, leading to a 17% increase in diluted EPS to $0.48 due to ongoing share buybacks.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.